Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Galantamine for Alzheimer's disease.

J Olin1, L Schneider

  • 1Adult and Geriatric Treatment and Preventative Interventions Branch, National Institute of Mental Health, NIMH, Room 7160, MSC 9635, 6001 Executive Blvd., Bethesda, Maryland 20892-9635, USA. jolin@mail.nih.gov

The Cochrane Database of Systematic Reviews
|July 26, 2002
PubMed
Summary

Galantamine demonstrates significant benefits for Alzheimer's disease (AD) patients, improving cognitive function and global ratings in trials of 3-6 months. Doses above 8mg/day showed consistent efficacy, with 16mg/day appearing well-tolerated and effective.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Performance and nutrient composition of black soldier fly larvae fed diets with various protein concentrations throughout the life cycle.

Animal : an international journal of animal bioscience·2025
Same author

Uptake of drug-reduced antiretroviral strategies and impact on costs over 2015-22: experience from an HIV clinic in Paris, France.

The Journal of antimicrobial chemotherapy·2025
Same author

Canadian Surgery Forum: Abstracts of presentations to the Annual Meetings of the Canadian Association of Bariatric Physicians and Surgeons, Canadian Association of General Surgeons, Canadian Association of Thoracic Surgeons, Canadian Hepato-Pancreato-Biliary Association, Canadian Society of Surgical Oncology, Canadian Society of Colon and Rectal Surgeons, Vancouver, BC, Sept. 17-21, 2013.

Canadian journal of surgery. Journal canadien de chirurgie·2025
Same author

No virological failure in patients living with HIV with past NNRTI resistance-associated mutations switched to doravirine-containing regimens.

The Journal of antimicrobial chemotherapy·2025
Same author

Knowledge, attitudes and practices on prevention and control of high-consequence infectious diseases and critical care among intensive care personnel in Rwanda: a cross-sectional survey.

Infection prevention in practice·2024
Same author

Extrahepatic Bile Duct Organoids as a Model to Study Ischemia/Reperfusion Injury During Liver Transplantation.

Transplant international : official journal of the European Society for Organ Transplantation·2024

Area of Science:

  • Pharmacology
  • Neuroscience
  • Clinical Trials

Background:

  • Galantamine is a reversible acetylcholinesterase inhibitor and allosteric modulator of nicotinic receptors.
  • Originally from daffodil bulbs, it is now synthesized and approved in 29 countries for Alzheimer's disease (AD).

Purpose of the Study:

  • To assess the clinical effects of galantamine in patients with probable AD.
  • To investigate potential moderators of galantamine's treatment effect.

Main Methods:

  • Systematic review of randomized, double-blind, placebo-controlled trials of galantamine in AD patients.
  • Data extraction and pooling of outcomes including ADAS-cog, CIBIC-plus, ADCS-ADL, DAD, and NPI.
  • Analysis of potential moderators such as trial duration and dosage.

Related Experiment Videos

Main Results:

  • Galantamine showed significant treatment effects at daily doses of 16-32 mg in trials of 3- to 6-months duration.
  • Statistically significant improvements were observed in global ratings and cognitive function (ADAS-Cog) for doses above 8mg/day.
  • Higher doses (24-32 mg/day) were associated with increased discontinuation rates, particularly at 32mg/day.

Conclusions:

  • Galantamine demonstrates consistent positive effects on global ratings, cognition, ADLs, and behavior in trials of 3-6 months.
  • The cognitive effect magnitude is comparable to other cholinesterase inhibitors.
  • An initial dose of 16 mg/day is suggested as it balances efficacy and tolerability, with longer-term effects remaining unassessed.